Opinion|Videos|November 8, 2024
MARIPOSA-2: Second-Interim Survival Data
Author(s)Hatim Husain, MD
Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for Medical Oncology Congress 2024, affect treatment strategies for patients with non–small cell lung cancer that has developed resistance to osimertinib.
Advertisement
Episodes in this series
Video content above is prompted by the following:
The second interim overall survival data from MARIPOSA-2 were presented at the European Society for Medical Oncology Congress 2024.
Please briefly discuss the updated data and the implications for second-line therapy for those currently receiving osimertinib, particularly when osimertinib is continued with platinum-based chemotherapy after resistance to osimertinib is noted.
Advertisement
Related to this article
SABR had higher 3-year all-cause mortality than surgery in early-stage NSCLC (30.3% vs 21.6%) in an emulated target trial; the gap narrowed at age 80 and older.
Hoth Therapeutics stopped the phase 2a CLEER-001 trial of topical HT-001 early after an interim review and will seek FDA input on phase 3.
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Real-world study shows outpatient tarlatamab for relapsed SCLC is feasible, with mostly low-grade CRS, rare ICANS, low ICU use, and similar disease control.
Catch up on October 2026 FDA oncology actions: approvals for pirtobrutinib, tucatinib, and dostarlimab, plus BLA and NDA submissions and a new designation.
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
Phase 3 data at ESMO 2026: sac-TMT and iza-bren beat chemotherapy in NSCLC, while chemo plus pembrolizumab extended PFS in PD-L1–high disease.
ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
Neoadjuvant Botensilimab/Balstilimab Shows Activity in Colon Cancer
5